Table 1 Baseline characteristics of the pilot RCT study population.

From: Functional and Transcriptomic Characterization of Peritoneal Immune-Modulation by Addition of Alanyl-Glutamine to Dialysis Fluid

Variable

 

Patients (n)

6

Sex (n) (male/female)

4/2

Age (y)

52.5 (45–68)

Body mass index (kg/m3)

23.90 (20.3–35.3)

Body surface area (m2)a

1.87 (1.73–2.01)

Time on PD (m)

17.8 (4.9–48.1)

Patients with residual renal output (n)

4

Residual renal urine outputb (ml)

2030 (1750–2500)

Residual renal clearanceb,c (ml/min/1.73 m2)

5.04 (3.2–8.3)

PD modality (n) (APD/CAPD)

5/1

Total weekly Kt/V (-)

2.39 (1.68–2.82)

History of previous peritonitis (n)

2

Transport typed (n) (high/high average)

3/3

  1. Data are presented as median (range). Body surface area was calculated with the Du Bois method. bMedian residual renal urine output and clearance were computed from 4 patients with residual renal output. cResidual renal clearance was calculated as mean of renal creatinine and renal urea clearance using 24 h urine samples. dTransport type was determined from the PET with standard 3.86% PDF.
Back to article page